JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kagoshima, H.
Right arrow Articles by Shigesada, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kagoshima, H.
Right arrow Articles by Shigesada, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 51, Issue of December 20, 1996 pp. 33074-33082
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Functional Dissection of the alpha  and beta  Subunits of Transcription Factor PEBP2 and the Redox Susceptibility of Its DNA Binding Activity*

(Received for publication, July 22, 1996, and in revised form, October 4, 1996)

Hiroshi Kagoshima Dagger , Yoshiko Akamatsu §, Yoshiaki Ito and Katsuya Shigesada par

From the Laboratory of Biochemistry, Department of Genetics and Molecular Biology, and the  Laboratory of Cell Regulation, Department of Viral Oncology, Institute for Virus Research, Kyoto University, Sakyo-ku, Kyoto 606, Japan

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

The mouse transcription factor PEBP2 is a heterodimer of two subunits: a DNA binding subunit alpha  and its partner subunit beta . The alpha  subunit shares a region of high homology, termed the Runt domain, with the products of the Drosophila melanogaster segmentation gene runt and the human acute myeloid leukemia-related gene AML1. To study the molecular basis for the DNA binding and heterodimerization functions of this factor, we constructed series of deletions of the alpha  and beta  subunits and examined their activities by electrophoretic mobility shift and affinity column assays. The minimal functional region of the alpha  subunit for DNA binding and dimerization was shown to coincide with the Runt domain. On the other hand, the region of the beta  subunit required for heterodimerization was localized to the N-terminal 135 amino acids. Furthermore, it was found that the DNA binding activity of the Runt domain is regulated by a reduction/oxidization (redox) mechanism and that its reductively activated state, which is extremely labile, is stabilized by the beta  subunit. These findings add a new layer to the mechanism and significance of the regulatory interplay between the two subunits of PEBP2.


INTRODUCTION

Transcription factor PEBP2 was originally identified from mice as a factor that binds to the core regions of polyomavirus enhancer, specifically recognizing a consensus sequence, (R/T)ACCRCA (1, 2). Purification of PEBP2 revealed that it is a complex of two different subunits, alpha  and beta  (2). PEBP2alpha directly binds to DNA. PEBP2beta does not directly interact with DNA, but it associates with the alpha  subunit to form a complex with greater DNA binding affinity. Binding sites for PEBP2 are also present in the core motifs of murine leukemia virus enhancer (3) as well as the regulatory regions of many cellular genes such as T-cell receptor (T-cell receptor alpha , beta , gamma , and delta ), CD3delta and CD2epsilon (4, 5), myeloperoxidase (6), and granulocyte-macrophage colony-stimulating factor (7). Several groups have independently identified transcription factors binding to these sites, variously referred to as CBF (3), SEF1 (8, 9), NF-delta E3A (4), and MyNF1 (6), which are probably identical or related to PEBP2. These observations imply that PEBP2 is important for hematopoietic gene regulation.

Significant insights into the structure and function of PEBP2 come from cloning and sequence analysis of cDNAs for each subunit (10, 11, 12). PEBP2alpha A, the first member of the alpha  subunit family to be identified (11), is structurally unrelated to any known transcription factors, but it shares a 128-amino acid region of high sequence homology to the Drosophila segmentation gene, runt (71% identity) (13), and the human AML1 gene (94% identity), a proto-oncogene identified at the breakpoint of chromosomal translocation t(8;21) that is associated with acute myeloid leukemia (14, 15). Thus, we have named this new group of regulatory proteins the Runt family and their conserved region the Runt domain, respectively (16). Two additional members of the Runt family, PEBP2alpha B (mouse homolog of AML1) (17) and PEBP2alpha C (18) or AML2 (19) have subsequently been identified in mice and humans. Moreover, gene disruption analysis in mice has suggested that AML1/PEBP2alpha B is essential for definitive hematopoiesis of all lineages (20, 21). The close link of PEBP2 to leukemogenesis is further reinforced by the discovery that the gene encoding the human homolog of the beta  subunit is located at the breakpoint of a chromosomal inversion, inv(16), associated with a M4Eo subtype acute myeloid leukemia (22). This gene rearrangement gives rise to a fusion product, PEBP2beta -MYH11, which contains the N-terminal 165 residues of the beta  subunit and the C-terminal portion of smooth muscle myosin heavy chain. These observations suggested that the alpha  and beta  subunits have been evolved as close partners and thereby play crucial roles in development and oncogenesis.

Prompted by the identification of the Runt domain, we set out to investigate its functional role(s). Preliminary deletion analysis suggested that the Runt domain is responsible for both DNA binding and heterodimerization with the beta  subunit (11, 16). In this study, we extended the deletion analysis with PEBP2alpha A in more detail to define the exact regions required for the two activities within the Runt domain. Analogous deletion analysis with PEBP2beta was also carried out to localize its functional domain for association with the alpha  subunit. We utilized these deletion constructs to further characterize the molecular and functional interactions between the two subunits. These studies led to the discovery that the DNA binding activity of the Runt domain can be sensitively controlled by a reduction/oxidization (redox) mechanism and that the beta  subunit acts to stabilize the activated state of the Runt domain, apart from and in addition to its known effect to increase the DNA binding affinity.


MATERIALS AND METHODS

Plasmid Construction

To produce alpha A1 and alpha A2, the two alternatively spliced isoforms of the PEBP2alpha subunit originally isolated (11), as fusions with an N-terminal hexahistidine (His) tag in Escherichia coli, their coding sequences were inserted between the BamHI and HindIII sites of expression vector pQE9 (Qiagen), resulting in pQE-alpha A1 and pQE-alpha A2, respectively. A series of truncations of alpha A were generated from the parental plasmid pQE-alpha A2 by cleaving at appropriate restriction sites within the alpha A coding sequence (Fig. 1). The N- and C-terminal deletions are designated alpha N and alpha C followed by numbers indicating the respective termini of the remaining region. Since pQE vector allowed only poor overexpression for alpha A1, alpha A2, alpha N94C306, and alpha N113C306, the EcoRI-HindIII fragments encoding these proteins in pQE were recloned into the XbaI site of a T7 promoter-driven expression plasmid vector, pET3a (23).


Fig. 1. Structure and activities of PEBP2alpha A deletion derivatives. Horizontal bars diagrammatically depict alpha  derivatives constructed. The shaded box stands for the Runt domain. The symbols in the left-hand columns indicate the DNA binding and heterodimerization activities as estimated from the results shown in Figs. 4 and 5: +, active; ±, weakly active; -, inactive. At the bottom are indicated the results of similar analysis previously reported for AML1 derivatives: GST-AML1a (16) and AML1-MTG8 (15). The arrows indicate the minimum region thus defined for DNA-binding (amino acids 113-220) and heterodimerization (amino acids 102-216), respectively.
[View Larger Version of this Image (28K GIF file)]


To produce N-terminally His-tagged beta  subunits, the coding sequences of three alternatively spliced isoforms, beta 1, beta 2, and beta 3, were inserted between the BamHI and SalI sites of plasmid pQE9. Furthermore, to produce N- or C-terminal dihydrofolate reductase (DHFR) fusions of beta  subunit, which also were His-tagged, the coding sequences of PEBP2beta 1 and PEBP2beta 2 subunits were inserted between the BamHI and HindIII sites of plasmid pQE13 (Qiagen). A series of deletions were introduced into beta  subunit by cleavage at the appropriate restriction sites (Fig. 2). The resulting beta  deletions were designated in the same way as described for alpha A deletions. Plasmid pET-beta 2 coding for the tagless beta 2 protein was described previously (10).


Fig. 2. Structure and activities of PEBP2beta deletion derivatives. The horizontal bars diagrammatically depict beta  derivatives constructed. The region shared by all three beta  isoforms is indicated by open boxes, and C-terminal divergent areas are variously decorated as follows. Darkly shaded, common to beta 1 and beta 2; lightly shaded, unique to beta 2; hatched, common to beta 1 and beta 3. The symbols in the left-hand columns indicate heterodimerization and DNA binding stimulation activities as estimated from the results shown in Fig. 6: +, active; ±, weakly active; -, inactive; NEG, inhibitory. The open and filled arrows indicate the minimum regions required for heterodimerization (amino acids 1-135) and simulating activity (amino acids 1-117), respectively.
[View Larger Version of this Image (41K GIF file)]


Production and Purification of PEBP2 alpha  and beta  Subunits

E. coli strain M15 with pQE plasmids and BL21 with pET plasmids were grown in LB broth and induced with 0.5 mM isopropyl beta -D-thiogalactoside. Harvested cells were lysed by suspending them in buffer A (0.1 M sodium phosphate, 10 mM Tris, 6 M guanidine-HCl, 1 mM phenylmethylsulfonyl fluoride, 10 mM beta -mercaptoethanol, and 0.1% Nonidet P-40, pH 8.0). The lysate was centrifuged at 15,000 rpm at 4 °C for 30 min, and the resulting supernatant was sonicated to break down DNA. The supernatant was applied onto a nickel nitrilotriacetic resin (Ni-NTA1 column) (Qiagen) and washed with buffer A containing 0.8 mM imidazole. His-tagged proteins were eluted with 12-250 mM stepwise imidazole gradients in buffer A containing 20% glycerol. The purified proteins were renatured by dialysis against 100 volumes of buffer D (0.1 M sodium phosphate, 10 mM Tris, 10 mM DTT, and 30% glycerol, pH 8.0) at 4 °C overnight. The SDS-polyacrylamide gel electrophoresis (SDS-PAGE) pattern of the purified alpha  and beta  derivatives after the step of the NTA column is shown in Fig. 3, A and B. Since alpha A1 recovered from the Ni-NTA column still contained substantial contaminants or its proteolytic degradation products, its full-length polypeptide was eluted from the SDS-polyacrylamide gel and renatured by dialysis as described previously (2). The tagless beta 2 protein was expressed from pET-beta 2 in E. coli and purified under nondenaturing conditions as described previously (10).


Fig. 3. SDS-PAGE patterns of alpha  and beta  derivatives. His-tagged derivatives of PEBP2alpha (A) and PEBP2beta (B) were purified with the NTA column, subjected to SDS-PAGE, and visualized by silver staining.
[View Larger Version of this Image (62K GIF file)]


Electrophoretic Mobility Shift Assay (EMSA)

A DNA probe containing the wild-type PEBP2 binding site was prepared by annealing an oligonucleotide pair, 5'-CATGGTAACT<UNL>GACCGCA</UNL>GAGGGC-3' and 5'-CATGGCCCTC<UNL>TGCGGTC</UNL>AGTTAC-3' (the PEBP2-binding site is underlined), and labeled with [alpha -32P]dATP in a standard reaction using the Klenow fragment. Unless specified otherwise, the DNA binding reaction (final volume, 10 µl) was routinely carried out at room temperature for 15 min in EMSA buffer (20 mM HEPES-KOH, 4% Ficoll, 2 mM EDTA, 1 mM DTT, 100 mM KCl, 0.1 µg of poly(dI-dC), 6% glycerol, 0.2 mg/ml bovine serum albumin, 0.04% bromphenol blue and 10 fmol of labeled probe). The reaction mixture was loaded on a 10% nondenaturing polyacrylamide gel (acrylamide:bisacrylamide, 39:1) in 0.25 × TBE (22.5 mM Tris borate and 0.5 mM EDTA, pH 8.0) and electrophoresed at room temperature.

Affinity Column Assay of alpha ·beta Subunit Association

To assay the heterodimerization activity of alpha  protein derivatives independent of their DNA binding activity, an affinity column assay was performed. About 1 µg of the His-tagged alpha  subunit and the tag-less beta 2 subunit (about 0.5 µg) were incubated in 100 ml of affinity column assay buffer (0.1 M sodium phosphate, 10 mM Tris, 1 mM beta -mercaptoethanol, and 20% glycerol, pH 8.0) at 4 °C for 30 min. The reaction mixture was loaded onto a Ni-NTA column. This column was successively washed with affinity column assay buffer containing 40 mM imidazole and 250 mM imidazole. Proteins eluted in each fraction were analyzed by SDS-PAGE followed by silver staining.


RESULTS

Functional Domain Analysis of PEBP2alpha A Subunit

To localize the minimal regions of PEBP2alpha A subunit required for its DNA binding and heterodimerization activities, we produced a series of its deletions as His-tagged forms in E. coli (Figs. 1 and 3A). The resultant alpha  derivatives were purified on a Ni-NTA column under denaturing conditions, renatured by dialysis, and subjected to EMSA in the presence and absence of the beta 2 subunit (Fig. 4). In this assay, the heterodimerization activity was readily detected by supershifts of protein-DNA complexes. In the pilot study with alpha A1 and alpha A2, the two alternatively spliced isoforms of PEBP2alpha A, we noticed that the 513-amino acid alpha A1 protein tended to undergo extensive proteolytic degradation in its C-terminal region either within bacterial cells or during the isolation procedure. Moreover, its full-length polypeptide, as purified by gel electrophoresis, gave a barely detectable bandshift in EMSA (however, see below for its assay under improved conditions). In contrast, the 306-amino acid alpha A2 protein was more resistant to proteolysis and showed a strong DNA binding activity at a relatively low dose of 5-10 ng/reaction. Hence, alpha A2 was used as the starting material for constructing the deletion from either end and also as the reference in comparing the DNA binding capacities of various alpha  protein constructs.


Fig. 4. DNA binding and complex formation assays of deleted variants of PEBP2alpha subunit by EMSA. The EMSA reaction was performed with the following deletions in specified amounts: alpha A1, 50 ng; alpha A2, 10 ng; alpha N94C306, 5 ng; alpha N113C306, 50 ng; alpha N140C306, 100 ng; alpha C226, 5 ng; alpha C216, 100 ng; alpha C202, 100 ng; alpha N94C226, 2 ng; alpha N113C226, 60 ng; DHFR, 100 ng. + and - indicate the presence and absence of the beta 2 subunit (100 ng).
[View Larger Version of this Image (47K GIF file)]


In the N-terminal deletion series, alpha N94C306 was as active as alpha A2 in both DNA binding and heterodimerization with the beta  subunit. The next deletion, alpha N113C306, was still weakly active in DNA binding but not in heterodimerization. Although this deletion gave two distinct bands, the lower one is supposed to represent a proteolytic degradation product, which tended to accumulate gradually during its storage. Further deletion to position 140 resulted in a complete loss of DNA binding activity, giving no discernible shifted band even when its dose was increased to 100 ng/reaction. In the C-terminal deletion series, alpha C226 was strongly active in DNA binding and heterodimerization, but the next further deletion, alpha C216, no longer showed any DNA binding activity. These results indicate that the minimal region for DNA binding resides between amino acids 113 and 226, although an additional segment up to amino acid 94 is further required for full activity. The region from amino acid 94 to 226 was similarly shown to be sufficient for the heterodimerization activity. However, its exact C-terminal boundary could not be determined by EMSA, because C-terminal deletions more extensive than alpha C226 did not bind to DNA. For such non-DNA binding deletions, we measured their heterodimerization activity by their ability to cause co-adsorption of tagless beta  subunit to a Ni-NTA column as described under "Materials and Methods." This direct assay indicated that the heterodimerization activity was still retained in alpha C216 but not in deletions with further C-terminal truncations (Fig. 5).


Fig. 5. Complex formation assays by protein-protein affinity column. The beta 2 subunit, not containing any histidine tag, was incubated with the following His-tagged proteins bound to Ni-NTA resin. Lane 1, alpha N80C226 as a positive control; lane 2, DHFR as a negative control; lane 3, alpha C226; lane 4, alpha C216; lane 5, alpha C202; lane 6, alpha C160. Bound proteins were eluted using a stepwise imidazole gradient as described under "Materials and Methods." Eluates were resolved by SDS-PAGE and visualized by silver staining. The electrophoretograms are shown only for the main fraction eluted with 250 mM imidazole.
[View Larger Version of this Image (42K GIF file)]


Taking all of these results together, we conclude that the functional regions for DNA binding (amino acids 113-226) and heterodimerization (amino acids 94-216) extensively overlap each other and encompass together almost the entire expanse of the Runt domain (amino acids 93-220) as originally defined from sequence homologies alone (16) (see "Discussion" for further detailed considerations). During this deletion analysis, we also noticed a general trend that alpha derivatives retaining the C-terminal sequence up to position 306 showed greater -fold stimulation in their DNA binding by the beta subunit than those lacking this region (Fig. 4, compare the lanes for alpha A1, alpha A2, and alpha N94C306 against those for alpha C226 and alpha N94C226). This suggested the intriguing possibility that the C-terminal region might act to modulate the regulatory interaction between the Runt domain and the beta  subunit. This issue will be readdressed below in reference to the redox regulation of the alpha  subunit function.

Functional Domain Analysis of PEBP2beta Subunit

We have previously reported that two isoforms of the beta  subunit, beta 1 and beta 2, and a beta 1-derived C-terminal deletion (beta 1C141) heterodimerize with the alpha  subunit, whereas the third isoform beta 3 cannot (10).

To extend that analysis, we constructed N- and C-terminal deletions of the beta  subunit (Figs. 2 and 3B) and tested their ability to interact with the minimal Runt domain fragment (alpha N94C226, referred to hereafter as the RD fragment) by EMSA (Fig. 6). In the C-terminal deletion series, which were readily produced and purified as His-tagged forms, those truncated up to amino acid 135 (beta 1C135) were functional, but the next further deletion (beta 1C117) became inactive. On the other hand, we were unable to produce any N-terminal deletions as His-tagged fusions, because the growth of bacterial hosts was severely inhibited upon their expression from plasmids encoding them. After various trials, we finally succeeded in overproducing them as N- or C-terminal fusions with DHFR. However, the N-terminal DHFR fusion with beta 1 (and also beta 2; data not shown) apparently inhibited the DNA binding by the RD fragment without showing any supershift. This implies that DHFR-beta 1 can interact with the Runt domain but that the resultant complex is inactive in DNA binding. In contrast, the corresponding C-terminal DHFR fusion with beta 1 produced a highly smeared supershifted band, suggesting that it formed a complex with the RD fragment being somewhat unstable, although active in DNA binding. On the other hand, N-terminal beta  deletions (beta 1N41, beta 1N55, beta 1N72, and beta 1N86) fused to DHFR on either end had no visible effect at all on the DNA binding signal due to the RD fragment (data not shown). Taken together, these results indicate that the N-terminal 135-amino acid region and its unperturbed steric or conformational state at the N-terminal end are important for its effective interaction with the Runt domain.


Fig. 6. Complex formation assays of beta  subunit deletions by EMSA. The RD fragment was subjected to EMSA together with increasing amounts of indicated beta  subunit variants (His-tagged). The amount of RD fragment was 3 ng for reactions with DHFR-beta 1 and 1 ng for the remainder. The amounts of beta  variants used in each set of lanes were from left to right were as follows: 0, 0.03, 0.3, 3, and 30 ng for DHFR-beta 1; 0, 0.06, 0.6, 6, and 60 ng for beta 1-DHFR; 2, 10, and 40 ng for the remainder.
[View Larger Version of this Image (32K GIF file)]


Surprisingly, beta 3 and beta 1C117 subunits caused notable stimulation in the DNA-binding activity of the RD fragment, although these subunits did not produce any supershifted band. This effect seems specific to beta  derivatives, since no such phenomenon was observed with other unrelated proteins such as DHFR (data not shown) and bovine serum albumin (always included in the EMSA buffer). We infer that these beta  subunits can interact with the RD fragment in solution to form heterodimers that bind more efficiently to DNA than does the RD fragment alone but that they may fall apart from the DNA·RD complex upon entering polyacrylamide gels. Such an event could happen if the association between those beta  derivatives and the RD fragment is substantially weaker than that between the RD fragment and DNA. Thus, the N-terminal 117 amino acids appear to contain the region minimally essential for the stimulating effect.

Redox Regulation of the Runt Domain Function

While performing EMSA as described above, we found that the DNA binding activity of alpha  subunit tended to decrease gradually during its storage but that such an aged sample could be effectively reactivated by incubation with a high concentration of sulfhydryl protecting agent, DTT (Fig. 7A, lane 2). Coincidentally, the three Runt family proteins identified in mouse and human share two conserved cysteine residues in their Runt domain sequence, and one of them (Cys124 in alpha A) is thought to be highly sensitive to oxidation, since it is surrounded by positively charged residues (24). These observations suggested to us that PEBP2 might be subject to the so-called redox regulation as had been known for Jun/Fos (25) and NF-kappa B (26).


Fig. 7. Effects of redox reagents and beta  subunit on the DNA binding activity of the RD fragment. A, the RD fragment (5 ng/reaction) was treated with diamide, DTT, or beta 2 subunit (50 ng), either individually or in succession as follows. Lane 1, no DTT supplemented (residual DTT carried over from the stock solutions of the RD fragment and the beta 2 subunit was approximately 0.01 mM); lane 2, 100 mM DTT; lane 3, 0.25 mM diamide; lane 4, 0.025 mM diamide; lane 5, beta 2 subunit; lane 6, beta 2 subunit followed by 100 mM DTT; lane 7, beta 2 subunit followed by 0.25 mM diamide; lane 8, 0.25 mM diamide followed by beta 2; lane 9, preoxidized beta 2 subunit (final concentration of diamide, 0.025 mM); lane 10, 0.25 mM diamide, beta  subunit, and DTT added successively. The incubation with each reagent was done at 25 °C for 10 min. B, the RD fragment preoxidized with 2.5 mM diamide as in A was incubated with varying concentrations of DTT (none supplemented (lane 1), 10 mM (lanes 2 and 6), 30 mM (lanes 3 and 7), 100 mM (lanes 4 and 8), 300 mM (lanes 5 and 9)) in the absence (lanes 1-5) or presence (lanes 6-9) of beta 2 subunit (50 ng) for another 10 min at 25 °C and then subjected to EMSA.
[View Larger Version of this Image (34K GIF file)]


To test this possibility, we systematically examined the effects of sulfhydryl reducing and oxidizing agents on the function of the Runt domain in EMSA. When the RD fragment was treated with a mild oxidant, diamide, its DNA binding activity was completely inhibited at 0.25 mM or more (Fig. 7A, lane 3). However, this lost activity was completely recovered by subsequent incubation with a molar excess of DTT (Fig. 7B). The restored activity increased proportionately with increments in the concentration of added DTT up to 300 mM as far as tested. Such an extreme dependence on DTT is characteristic of redox-responsive DNA binding proteins (24, 25, 26). Interestingly, the oxidative inactivation of the RD fragment was effectively prevented by the addition of the beta  subunit before but not after the treatment with diamide (Fig. 7A, compare lanes 7 and 8 with lane 5 as a control). However, the beta  subunit did not interfere with the reductive reactivation of the preoxidized RD fragment when it was added before DTT (Fig. 7A, compare lanes 8 and 10). Thus, the beta  subunit may selectively act to mask the putative redox-sensitive cysteine residue(s) of the Runt domain from the action of diamide but not DTT, either by steric hindrance or through conformational influence. This implies that the beta  subunit could promote the reduction of the RD fragment either in its reaction kinetics or in its overall equilibrium. In accord with this view, the beta -dependent -fold increase in the DNA activity was apparently greater at lower concentrations of DTT (Fig. 7B, compare lanes 2-5 versus lanes 6-9). To further investigate this issue, we compared the time course of the reductive activation of the RD fragment in the presence and absence of the beta  subunit. The result showed that the reactivation could actually take place with similar rapidity with or without the beta  subunit, rising to half of the maximal level already at the earliest time of sampling (0.5 min) and reaching a peak at 10 min after the addition of DTT (Fig. 8, A and B, left parts). Rather surprisingly, the resumed activity of the RD fragment by itself began to rapidly diminish thereafter to less than one-fourth the peak level at 30 min and almost null at 60 min. In a dramatic contrast, little inactivation occurred in the presence of the beta  subunit. Since the inactivation of the RD fragment proceeded despite the presence of a vast molar excess of DTT, it could not be due to a simple reoxidation, but it might involve some other irreversible processes such as thermal protein denaturation or oxyradical reaction. In any case, these observations have disclosed that the activated state of the RD fragment is extremely labile and that it can be greatly stabilized by the association with the beta  subunit.


Fig. 8. Time course of reactivation of the RD fragment and alpha A1 by DTT. A, EMSA patterns. The RD fragment (5 ng/10 µl, left part) and alpha A1 (50 ng/10 µl, right part) were preoxidized with 2.5 mM diamide at 25 °C for 10 min and then reactivated with 100 mM DTT in the absence and presence of beta 2 subunit (50 ng). At indicated times after the addition of DTT, samples were taken out and immediately loaded to a nondenaturing polyacrylamide gel, which was kept running continuously. B, graphs showing changes with time in the DNA binding activities of the RD fragment (left panel) and alpha A1 (right panel) and their -fold stimulation by beta  subunit. The intensity of shifted bands detected above was quantitated with a phosphor imager (Fuji BAS 2000) and plotted against time. open circle  and bullet , the fraction of DNA bound in the absence and presence of beta  subunit, respectively; square , -fold stimulation by beta  subunit.
[View Larger Version of this Image (44K GIF file)]


We also performed similar analyses with the intact alpha A1 protein (Fig. 8A, right panel). It showed essentially the same patterns of activation by DTT and protection by the beta  subunit as did the RD fragment, except that its activated state was even more unstable than that of the RD fragment. The activity of alpha A1 alone was completely lost within 30 min, and it diminished to less than one-third the peak level at 60 min even in the presence of the beta  subunit (Fig. 8B, right part). In consequence, its DNA binding activity turned out to appear almost absolutely dependent on the beta  subunit when the incubation was kept longer than 10 min (see the dashed lines in Fig. 8B). Retrospectively, this circumstance may explain why the DNA binding activity of alpha A1 appeared to be so weak and stringently depended on the beta  subunit in the earlier EMSA analysis (Fig. 4), in which the DTT concentration was insufficient (1 mM) and the incubation time was longer than optimal (15 min).

Quantitative Reevaluation of the Functional Roles of the beta  Subunit in DNA Binding by PEBP2

Ogawa et al. (10) have previously reported that the intrinsic function of the beta  subunit is to decrease the dissociation constant (Kd) of the a subunit for DNA without changing its maximal binding capacity (Pmax) (10). As described in the preceding section, however, the beta  subunits could also augment the apparent Pmax level through its protective action in a manner dependent on both the redox state and the structural context of the alpha  subunit. To evaluate these dual functional contributions of the beta  subunit more quantitatively, we studied the DNA binding kinetics of both the RD fragment and alpha A1 by EMSA in the presence or absence of the beta  subunit at low and high concentrations of DTT (Fig. 9). In this analysis, extreme care was taken to perform the EMSA manipulations at a constant and optimal timing, so that the DNA-protein complex could be applied to gel electrophoresis while it stayed at a maximally activated state. In the assay of the RD fragment (Fig. 9A) with 10 mM DTT, the beta  subunit caused not only a severalfold decrease in the Kd (from 1.4 to 0.2 nM) but also a substantial increase in the Pmax (about 2-fold). By contrast, the Pmax was increased at 100 mM DTT to nearly the same level either in the presence or absence of the beta  subunit. Under this assay condition, the beta  subunit solely exhibited the Kd effect.


Fig. 9. Effects of reducing conditions and the beta  subunit on the DNA binding affinity of the alpha  subunit. The RD fragment (5 ng/10 µl, panel A) and alpha A1 (50 ng/10 µl, panel B) were preoxidized at 25 °C for 10 min with 2.5 mM diamide and then incubated for 10 min with 10 or 100 mM DTT in the absence or presence of beta 2 subunit (50 ng) together with varying concentrations of probe DNA. open circle , 10 mM DTT; bullet , 10 mM DTT and beta 2; square , 100 mM DTT; black-square, 100 mM DTT and beta 2. Curves were generated by using the following equation: Bound DNA = Pmax × [free DNA]/(Kd + [free DNA]).
[View Larger Version of this Image (17K GIF file)]


In the case of the full-length alpha A1 protein (Fig. 9B), the beta  subunit similarly caused a decrease in the Kd value at either concentration of DTT tested. However, the absolute magnitude of its Kd in the presence of beta  (around 0.4 nM) was noticeably higher than that obtained with the RD fragment (0.2 nM). In addition, the effect of beta  to augment the Pmax was still observed at the higher DTT concentration (about 3-fold). By extrapolations from the result shown in Fig. 8B, a 3-fold inactivation of the alpha A1 protein could readily occur in the absence of the beta  subunit during the 10 min of incubation as adopted.


DISCUSSION

The results of this study lend support to and further refine our previous proposal that the Runt domain is a structural core responsible for both DNA binding and heteromeric protein-protein interaction (summarized in Fig. 1). The present deletion analysis localized the DNA binding and heterodimerization domain within amino acids 113-226 and 94-216, respectively. If other available evidence is also taken into account, the respective functional regions can be further confined within the conserved region originally defined from sequence homology between the Runt protein and AML1 (27). The DNA binding activity has been demonstrated in various Runt family proteins and their chimeric derivatives that have variable sequences distal to the C-terminal end of their Runt domain (amino acid 220 in alpha A). The heterodimerization activity was similarly detected in a deletion product of AML1 containing amino acids 59-190, which corresponds to amino acids 102-233 in alpha A (16). The localization of the dual functions in the same Runt domain for its whole expanse may explain why its sequence has been conserved so highly from insects to mammals. Intriguing from both the mechanistic and experimental points of view is the finding that the regions for DNA binding and heterodimerization are slightly staggered from each other by several amino acids toward the C-terminal and N-terminal ends, respectively. Although the DNA binding activity is detectable in alpha N113C306 or alpha N113C226, its magnitude per protein basis is much less than that of the full Runt domain fragment (cf. legend to Fig. 4). Evidently, therefore, the adjacent N-terminal segment, at least up to amino acid 93, is functionally important not only for heterodimerization with the beta  subunit but also for efficient DNA binding. This N-terminal proximal region may be directly involved in both DNA binding and its regulatory modulation by the beta  subunit. In support of this view, we have recently observed that a mutation in amino acid 97 (Ile right-arrow Thr) can cause a marked change in the DNA binding activity (28). Suggestive further in this connection is that this region is spatially close to and hence could be functionally interrelated with the two cysteine residues (Cys115 and Cys124) that are implicated in the redox regulation of the Runt domain function as discussed below. By contrast, the 4-amino acid segment on the C-terminal side (217-220, REPR) is dispensable for heterodimerization, but it is essential for DNA binding. Thus, deletions or site-directed mutagenesis of these segments would be useful in constructing mutants of the alpha  subunit differentially altered in DNA binding or heterodimerization, which should provide valuable probes for studying the regulatory interplay between the alpha  and beta  subunits of PEBP2 in vivo.

The parallel deletion analysis with the beta  subunit has revealed that the first 135 amino acids are required for its stable association with the alpha  subunit as monitored by supershifts of EMSA bands (summarized in Fig. 2). Recently, Drosophila has been shown to possess two kinds of beta  homologs, designated Brother (Bro) and Big brother (Bgb) (29). These two proteins share high homologies with the N-terminal 137 amino acid of the mouse beta  subunit except for a diverged internal segment that corresponds to positions 69-86. In a fair agreement with our results, a deletion of Bro containing the first 132 amino acids (137 in mouse beta ) was fully active in heterodimerization with its cognate partner Runt, but shorter derivatives lacking the first seven amino acids or ending at position 127 (132 in mouse beta ) were not. Furthermore, it was also reported that the heterodimerization activity was undetectable or significantly weakened in mammalian beta  subunit derivatives that retained only the first 133 amino acids: the mouse beta 3 (Ref. 10 and this work) and an internal deletion product (CDC32/M) of the human CBFbeta -SMMC chimera (22). From these observations, the two conserved amino acids at positions 134 and 135 (Glu and Asp) might be important for an efficient interaction between the alpha  and beta subunits.

On the other hand, the capacity of beta  to enhance DNA binding was mapped within the first 117-amino acid region. This implies the occurrence of weak but functionally significant interactions between the N-terminal proximal region of beta  and the Runt domain. Moreover, the fusion of DHFR to the intact beta 1 subunit caused inhibition, rather than stimulation, of DNA binding, suggesting that it could interact with the alpha  subunit, although in an unproductive way. The bulky DHFR moiety may either act as a direct steric block against the access of the alpha  subunit to DNA or induce an unfavorable conformation change in the alpha ·beta complex. If this is the case, the DHFR-beta fusion might be useful as a dominant negative mutant in studying the functional role of the beta  subunit in vivo.

The redox regulation mechanism has previously been known for a number of transcription factors such as Jun/Fos (25, 30), Myb (31, 32), NF-kappa B (26), and Ets-1 (33). Their DNA binding activity is greatly stimulated by sulfhydryl protecting agents such as DTT and mercaptoethanol or by cellular redox cofactors, Ref1/APEX for Jun/Fos (34, 35) and ADF/thioredoxin for NF-kappa B (36). These factors contain cysteine residues that are surrounded by basic amino acids and hence made hypersensitive to oxidation (24). Under insufficient reducing conditions or upon exposure to a mild oxidant, typically diamide, the thiol moiety of such cysteines is readily converted into a more acidic state that is inhibitory to DNA binding, although the exact chemical nature of this inactivated state remains to be determined. The present study has revealed that the DNA binding activity of PEBP2alpha requires the presence of a high concentration of DTT and is conversely inactivated by diamide in a manner closely mimicking the above noted precedent. In addition, the Runt domain of PEBP2alpha contains two conserved cysteines, one of which is surrounded by basic amino acids (Arg-Cys124-Asn-Lys) and located close to the N-terminal boundary of the minimal DNA binding region. Thus, it is very likely that PEBP2alpha is also subject to the redox regulation. Notable here is that the Drosophila Runt protein is also redox-sensitive,2 although it has serine at the position corresponding to the Cys124 residue. Instead, the Runt protein contains three extra cysteines, two of which are flanked by basic amino acids and, hence, could be redox-sensitive.

Further investigations of the redox sensitivity of the Runt domain have led us to the additional findings of potential mechanistic and biological importance that its activated state is extremely unstable and that the beta  subunit has a remarkable protective effect on this activated state. This effect, as reflected by an apparent increase in the maximal DNA binding capacity (Pmax effect), is distinct from and manifests in superposition to the known function of beta  to increase the intrinsic DNA binding affinity (Kd effect) (10). While the Kd effect is relatively constant and modest (2-3-fold and 5-7-fold with alpha A1 and the RD fragment, respectively), the Pmax effect is extremely variable with assay conditions. When the DTT concentration was sufficiently high and the reaction time in EMSA was kept short (10 min), this effect was minimized to near unity with the RD fragment and 2-3-fold with alpha A1. If one or both of these conditions were inadequate, the DNA binding activity of the Runt domain by itself could rapidly diminish to an undetectable level with a concomitant upshoot in the Pmax effect (see dashed lines in Fig. 8). Thus, the incidence of beta -dependent stimulation by more than severalfold should be taken as a potential symptom of ill-suppressed inactivation of the alpha  subunit without the beta  subunit. Such a situation might be relevant to the Drosophila Runt protein, whose DNA binding activity was reported to be almost absolutely dependent on its cognate beta  subunit, Bro or Bgb (29), or the mouse PEBP2beta (16). Although it was speculated that the Runt protein by itself, unlike its mammalian homologs, might favor a conformation that could bind to DNA poorly (29), it remains to be tested whether this protein alone could show appreciable DNA binding activity under improved conditions.

Apart from the preceding stability issue, a slight but noticeable difference was also observed between the RD fragment and the intact alpha A1 in their absolute Kd values attainable in the presence of the beta  subunit (0.2 and 0.4 nM for the RD fragment and alpha A1, respectively). The higher Kd value of alpha A1, together with its weaker beta -mediated protection, suggests the possibility that the C-terminal region present in the intact alpha A1 might exert negative steric or conformational influence on the interaction between the Runt domain and the beta  subunit. Similar views have also been presented from functional studies with PEBP2alpha B/AML1 in vivo and in vitro. The DNA binding activity of the mouse alpha B subunit is considerably strengthened when its 60-amino acid sequence immediately C-terminal to the Runt domain is displaced either by in vitro DNA recombination or by natural alternative splicing (37); the human 250-amino acid AML1a protein has a stronger DNA binding affinity than do the longer isoform AML1b (equivalent to mouse alpha B1) and the AML1-Evi1 chimeric protein (38); alpha B1 derivatives deleted of regions outside the Runt domain are more potent than the intact one in their ability to promote the translocation of the beta  subunit from the cytoplasm to the nucleus (39). Such intramolecular functional modulations of the Runt domain proteins and their chimeric derivatives could have important implications in hematopoietic differentiation and leukemogenesis, as frequently suggested (16, 37, 38, 39, 40). Thus, it would be interesting to make detailed comparative analysis of these proteins with respect to their DNA binding and heterodimerization functions under improved assay conditions established here.

A number of crucial questions remain regarding 1) the identity of the physiological reducing agent, 2) which one of the two conserved cysteine residues is the actual target of redox regulation, and 3) whether the redox regulation of PEBP2 occurs in vivo and, if so, what its exact regulatory significance is. As for question 1, we have found that DTT can be effectively substituted by thioredoxin/ADF or Ref1/APEX.3 To address question 2, we are carrying out site-directed mutagenesis of the two cysteine residues. Preliminary results suggest that the both cysteines are important.4 Regarding the most crucial question, question 3, Fos/Jun and NF-kappa B would again serve as suggestive precedents (41). In the Fos oncoprotein, a point mutation of the redox-sensitive cysteine residue to serine caused increases in its DNA binding activity in vitro as well as its transformation potential in vivo (42). As a similar, naturally occurring mutant, the v-Jun oncoprotein has a serine residue at the position corresponding to the redox-sensitive cysteine in the c-Jun proto-oncoprotein (43). NF-kappa B has also been implicated in the redox-dependent regulation of various cellular and viral genes specifically expressed in lymphoid cells such as cytokines (interleukin-2, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha , and interleukin-6) and their receptors (interleukin-2 receptor alpha  chain and major histocompatibility complex class I genes (reviewed in Ref. 44), and human immunodeficiency virus long terminal repeat (45, 46). Since the PEBP2/AML1 protein family is also essential for a similar repertoire of lymphoid-specific genes and differentiation of hematopoietic cell lineages as outlined in the Introduction, it is tempting to speculate that its redox regulation might have important roles, similar to the case of NF-kappa B. Work is under way to experimentally address this possibility in vivo by exploiting the above noted mutants of PEBP2alpha with altered redox responses.


FOOTNOTES

*   This study was supported in part by Ministry of Education, Science, Culture and Sports of Japan Research Grants 06280215 and 07272221 (to K. S.) and by a grant from the Human Frontier Science Program Organization. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Present address: Biozentrum, Der Universitat Basel, Abteilung Zellbiologie, Klingelbergstrasse 70, CH-4056 Basel, Switzerland.
§   Supported by a research fellowship from the Japan Society for the Promotion of Science for Young Scientists. Present address: Dept. of Molecular Biology, Massachusetts General Hospital, 50 Blossom St., Boston, MA 02214.
par    To whom correspondence should be addressed. Tel.: 075-751-4018; Fax: 075-751-3992; E-mail: kshigesa{at}virus.kyoto-u.ac.jp.
1    The abbreviations used are: Ni-NTA, nickel nitrilotriacetic; DTT, dithiothreitol; PAGE, polyacrylamide gel electrophoresis; EMSA, electrophoretic mobility shift assay; DHFR, dihydrofolate reductase; RD, Runt domain; ADF, adult T cell leukemia-derived factor.
2    Y. Akamatsu, unpublished observation.
3    Y. Akamatsu, unpublished data.
4    T. Ohno, Y. Akamatsu, J. Yodoi, and K. Shigesada, unpublished observation.

REFERENCES

  1. Satake, M., Ibaraki, T., and Ito, Y. (1988) Oncogene 3, 69-78
  2. Kamachi, Y., Ogawa, E., Asano, M., Ishida, S., Murakami, Y., Satake, M., Ito, Y., and Shigesada, K. (1990) J. Virol. 64, 4808-4819 [Abstract/Free Full Text]
  3. Wang, S., and Speck, N. A. (1992) Mol. Cell. Biol. 12, 89-102 [Abstract/Free Full Text]
  4. Leiden, J. M. (1992) Immunol. Today 13, 22-30 [CrossRef][Medline] [Order article via Infotrieve]
  5. Redondo, J. M., Pfohl, J. L., Hernandez-Munain, C., Wang, S., Speck, N. A., and Krangel, M. S. (1992) Mol. Cell. Biol. 12, 4817-4823 [Abstract/Free Full Text]
  6. Suzow, J., and Freedman, A. K. (1993) Mol. Cell. Biol. 13, 2141-2151 [Abstract/Free Full Text]
  7. Takahashi, A., Satake, M., Yamaguchi-Iwai, Y., Bae, S. C., Lu, J., Maruyama, M., Zhang, Y. W., Oka, H., Arai, N., Arai, K., and Ito, Y. (1995) Blood 86, 607-616 [Abstract/Free Full Text]
  8. Thornell, A., Hallberg, B., and Grundstrom, T. (1988) Mol. Cell. Biol. 8, 1625-1637 [Abstract/Free Full Text]
  9. Boral, A. L., Okenquist, S. A., and Lenz, J. (1989) J. Virol. 63, 76-84 [Abstract/Free Full Text]
  10. Ogawa, E., Inuzuka, M., Maruyama, M., Satake, M., Naito-Fujimoto, M., Ito, Y., and Shigesada, K. (1993) Virology 194, 314-331 [CrossRef][Medline] [Order article via Infotrieve]
  11. Ogawa, E., Maruyama, M., Kagoshima, H., Inuzuka, M., Lu, J., Satake, M., Shigesada, K., and Ito, Y. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6859-6863 [Abstract/Free Full Text]
  12. Wang, S., Wang, Q., Crute, B. E., Melnikova, I. N., Keller, S. R., and Speck, N. A. (1993) Mol. Cell. Biol. 13, 3324-3339 [Abstract/Free Full Text]
  13. Kania, M. A., Bonner, A. S., Duffy, J. B., and Gergen, J. P. (1990) Genes & Dev. 4, 1701-1713 [Abstract/Free Full Text]
  14. Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., and Ohki, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10431-10434 [Abstract/Free Full Text]
  15. Miyoshi, H., Kozu, T., Shimizu, K., Enomoto, K., Maseki, N., Kaneko, Y., Kamada, N., and Ohki, M. (1993) EMBO J. 12, 2715-2721 [Medline] [Order article via Infotrieve]
  16. Kagoshima, H., Shigesada, K., Satake, M., Ito, Y., Miyoshi, H., Ohki, M., Pepling, M., and Gergen, J. P. (1993) Trends Genet. 9, 338-340 [CrossRef][Medline] [Order article via Infotrieve]
  17. Bae, S. C., Yamaguchi-Iwai, Y., Ogawa, E., Maruyama, M., Inuzuka, M., Kagoshima, H., Shigesada, K., Satake, M., and Ito, Y. (1993) Oncogene 8, 809-814 [Medline] [Order article via Infotrieve]
  18. Bae, S. C., Takahashi, E., Zhang, Y. W., Ogawa, E., Shigesada, K., Namba, Y., Satake, M., and Ito, Y. (1995) Gene (Amst.) 159, 245-248 [CrossRef][Medline] [Order article via Infotrieve]
  19. Levanon, D., Negreanu, V., Bernstein, Y., Bar-Am, I., Avivi, L., and Groner, Y. (1994) Genomics 23, 425-432 [CrossRef][Medline] [Order article via Infotrieve]
  20. Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., and Downing, J. R. (1996) Cell 84, 321-330 [CrossRef][Medline] [Order article via Infotrieve]
  21. Wang, Q., Stacy, T., Binder, M., Marrin-Padilla, M., Sharpe, A. H., and Speck, N. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3444-3449 [Abstract/Free Full Text]
  22. Liu, P., Tarle, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., and Collins, F. S. (1993) Science 261, 1041-1044 [Abstract/Free Full Text]
  23. Rosenberg, A. H., Lade, B. N., Cui, D.-S., Lin, S.-W., Dunn, J. J., and Studier, F. W. (1987) Gene (Amst.) 56, 125-135 [CrossRef][Medline] [Order article via Infotrieve]
  24. Snyder, G. H., Cennerazzo, M. J., Karalis, A. J., and Field, D. (1981) Biochemistry 20, 6509-6519 [CrossRef][Medline] [Order article via Infotrieve]
  25. Abate, C., Luk, D., and Curran, T. (1990) Cell Growth. & Differ. 1, 455-462 [Abstract]
  26. Toledano, M. B., and Leonard, W. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4328-4332 [Abstract/Free Full Text]
  27. Daga, A., Tighe, J. E., and Calabi, F. (1992) Nature 356, 484 [Medline] [Order article via Infotrieve]
  28. Akamatsu, Y., Tsukumo, S., Kagoshima, H., Tsurushita, N., and Shigesada, K. (1996) Gene (Amst.), in press
  29. Golling, G., Li, L., Pepling, M., Stebbins, M., and Gergen, J. P. (1996) Mol. Cell. Biol. 16, 932-942 [Abstract]
  30. Ng, L., Douglas, F., and Curran, T. (1993) Nucleic Acids Res. 21, 5831-5837 [Abstract/Free Full Text]
  31. Grasser, F. A., LaMontague, K., Whittaker, L., Stohr, S., and Lipsick, J. S. (1992) Oncogene 7, 1005-1009 [Medline] [Order article via Infotrieve]
  32. Guehmann, S., Vorbrueggen, G., Kalkbrenner, F., and Moelling, K. (1992) Nucleic Acids Res. 20, 2279-2286 [Abstract/Free Full Text]
  33. Wasylyk, C., and Wasylyk, B. (1993) Nucleic Acids Res. 21, 523-529 [Abstract/Free Full Text]
  34. Xanthoudakis, S., and Curran, T. (1992) EMBO J. 11, 653-665 [Medline] [Order article via Infotrieve]
  35. Seki, S., Akiyama, K., Watanabe, S., Hatsushika, M., Ikeda, S., and Tsutsui, K. (1991) J. Biol. Chem. 266, 20797-20802 [Abstract/Free Full Text]
  36. Matthews, J. R., Wakasugi, N., Virelizier, J., Yodoi, J., and Hay, R. T. (1992) Nucleic Acids Res. 20, 3821-3830 [Abstract/Free Full Text]
  37. Bae, S. C., Ogawa, E., Maruyama, M., Oka, H., Satake, M., Shigesada, K., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., and Ito, Y. (1994) Mol. Cell. Biol. 14, 3242-3252 [Abstract/Free Full Text]
  38. Tanaka, T., Tanaka, K., Ogawa, S., Kurokawa, M., Mitani, K., Nishida, J., Shibata, Y., Yazaki, Y., and Hirai, H. (1995) EMBO J. 14, 341-350 [Medline] [Order article via Infotrieve]
  39. Lu, J., Maruyama, M., Satake, M., Bae, S. C., Ogawa, E., Kagoshima, H., Shigesada, K., and Ito, Y. (1995) Mol. Cell. Biol. 15, 1651-1661 [Abstract]
  40. Mitani, K., Ogawa, S., Tanaka, T., Miyoshi, H., Kurokawa, M., Mano, H., Yazaki, Y., Ohki, M., and Hirai, H. (1994) EMBO J. 13, 504-510 [Medline] [Order article via Infotrieve]
  41. Shulze-Osthoff, K., Los, M., and Baeuerle, P. A. (1995) Biochem. Pharmacol. 50, 735-741 [CrossRef][Medline] [Order article via Infotrieve]
  42. Okuno, H., Akahori, A., Sato, H., Xanthoudakis, S., Curran, T., and Iba, H. (1993) Oncogene 8, 695-701 [Medline] [Order article via Infotrieve]
  43. Bohmann, D., Bos, T. J., Admon, A., Nishimura, T., Vogt, P. K., and Tjian, R. (1987) Science 238, 1386-1392 [Abstract/Free Full Text]
  44. Baeuerle, P. A., and Henkel, T. (1994) Annu. Rev. Immunol. 12, 141-179 [Medline] [Order article via Infotrieve]
  45. Hayashi, T., Ueno, Y., and Okamoto, T. (1993) J. Biol. Chem. 268, 11380-11388 [Abstract/Free Full Text]
  46. Schreck, R., Rieber, P., and Baeuerle, P. A. (1991) EMBO J. 10, 2247-2258 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore